Sareum Holdings plc

(“Sareum” or the “Company”)

Exercise of Warrants and Total Voting Rights

Cambridge, UK, 14 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that it has received notice to exercise certain warrants to subscribe for new ordinary shares of 0.025p each in the capital of the Company (“New Ordinary Shares”) at a price of 2.8 pence per share. The aggregate gross proceeds of the exercise receivable by the Company amounts to approximately £180,000, which will be used for general working capital purposes.

The Company will make an application to the London Stock Exchange plc for the 6,428,571 New Ordinary Shares, to be issued and allotted as a result of the warrant exercises set out above, to be admitted to trading on AIM (“Admission”). It is expected that Admission will become effective and dealings will commence on or around 20 July 2021. The 6,428,571 New Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Following Admission, there will be 3,339,294,222 Ordinary Shares in issue. This number may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company.

For further information, please contact: 

Sareum Holdings plc

Tim Mitchell, CEO

 

 

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

 

 

020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce

 

 

020 3764 2341

MEDiSTRAVA Consulting (Financial PR)

Mark Swallow / David Dible

 

020 7638 9571

 

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com

- Ends -

 

  • @Sareumplc Latest tweet

    RT @HybridanLLP: Good to see Sareum's research on TYK2 as an oncology target referenced here. We see Sareum as a frontrunner in this space… via @Sareumplc
    View more